Q1 16 revenue came in ahead of our expectations with revenue growth of 8% (all revenue growth numbers at CER unless specified otherwise) to £6.2bn. FX tailwinds added another 3pp to the growth. HIV (+57%) remained the saving grace in the pharma business, and covered up the 9% decline in the non-HIV business, limiting the division’s decline to 1% (although it grew by 5% pro forma). It was followed by Consumer Healthcare (+26%) and Vaccines (+23%, 14% pro forma). The new products &n ....